Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACITO: FMT in Advanced Renal Cell Carcinoma
NCT04758507Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Donor FMT with Placebo FMT (2 arms). Primary endpoint: Progression-Free Survival at 12 months. Started Feb 2021; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04758507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758507.